Nomic Bio Secures Major Funding for Growth
Nomic Bio, a frontrunner in the field of protein profiling, has successfully wrapped up an oversubscribed Series B funding round, raising $42 million. This significant influx of capital marks an important milestone in Nomic's development and will facilitate further growth and innovation in their commercial endeavors. The funds will mainly focus on improving the capabilities of their advanced protein profiling platform and expanding their services to meet the growing demand across various sectors.
Capital Supported by Distinguished Investors
The Series B investment round received considerable backing from a diverse range of investors. Noteworthy among them is a leading U.S.-based investor specializing in life sciences that spearheaded the round. Other participants included Amplitude Ventures, AVANT BIO, Lux Capital, Real Ventures, and SR One, all showing strong faith in Nomic's vision and potential. This latest funding success brings Nomic's total capital raised to over $60 million, reflecting a growing confidence in the company’s goals and abilities within the biotech scene.
The Future of Proteomics Technology
Byron Hewett, a respected figure in the industry and current board member at Nomic, shared his thoughts about the future of proteomics. He stated, “Proteomics has the potential to drive the next generation of therapeutics and diagnostics.” According to Hewett, the success of proteomics technologies depends on their scalability and data accuracy. He also highlighted the necessity of making these technologies accessible and adaptable, allowing for widespread adoption across a range of industries.
Nomic’s Influence on the Biotech Landscape
Nomic has established itself as a transformative player in proteomics, empowering over 75 companies, which include prominent pharmaceutical firms, innovative biotech startups, and esteemed research institutions. Together, these entities have profiled more than 400,000 samples using Nomic’s cutting-edge nELISA™ platform. In response to the rising demand for their services, Nomic has initiated the development of industrial-scale facilities that leverage the impressive capabilities of their nELISA technology, ensuring clients receive comprehensive protein profiling services with unmatched throughput and rapid turnaround times.
CEO Insights on Nomic's Vision
Milad Dagher, CEO and Co-founder of Nomic, expressed his excitement about the company's direction. He noted, “Nomic was founded to help scientific teams succeed in their mission to extend health spans.” As Nomic makes significant advancements towards expanding its biological footprint, Dagher looks forward to revealing numerous new applications that will address a wide variety of use cases and disease areas. With the support of a distinguished group of investors, Nomic is set to realize its ambitious vision.
About Nomic
Nomic is committed to making protein profiling more accessible across various sectors. At the heart of their innovative strategy is the nELISA platform, which is proprietary technology that enables massive multiplexing, complete quantification, and exceptional cost efficiency. Their comprehensive approach to inflammation research allows for high-throughput quantification of hundreds of secreted proteins, while striving to encompass a broad range of proteins across the entire proteome. This expansion opens up unparalleled possibilities in different applications and areas within scientific research.
Frequently Asked Questions
What is the purpose of Nomic's recent funding round?
The funding will enhance Nomic's protein profiling platform and expand commercial operations to meet growing demand.
Who are some of the investors involved in Nomic's Series B round?
The investment round included notable names like Amplitude Ventures, AVANT BIO, Lux Capital, Real Ventures, and SR One.
What is nELISA, and why is it important?
nELISA is Nomic’s proprietary technology that offers comprehensive protein profiling, enabling massive multiplexing and accurate quantification, which is crucial for advancing research in proteomics.
How many companies has Nomic empowered?
Nomic has empowered over 75 organizations, including leading pharmaceutical firms and biotech companies, in their protein profiling efforts.
What are Nomic's future plans?
Nomic plans to broaden its biological footprint and discover new applications for its technology in various research areas, enhancing its role in drug discovery.
